Harrow, Inc.
HROWHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHarrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. The $1.74B market capitalization puts HROW squarely in small-cap range for its industry. It operates through Branded and ImprimisRx segments.
Market Cap
$1.74B
Beta
0.26
P/E (TTM)
—
P/E (Fwd)
17.43
EPS (TTM)
$-0.38
EPS (Fwd)
$2.68
ROE
-35.4%
ROA
3.1%
Cash
$96.0M
Total Debt
$300.7M
Free CF
-$5.0M
52W Change
30.0%
Annual Financials
Cash vs Debt
The company holds $96.0M in cash, though total debt stands at $300.7M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$5.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -35.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.1% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $88.6M (2022) to $272.3M (2025), reflecting a 207% increase over the period.
With a beta below 0.7, Harrow, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Harrow, Inc. and its sector.